Related Experiment Videos
[Clinical study on norfloxacin in children]
Insights
Norfloxacin, a new antibacterial drug, demonstrated 100% efficacy in treating pediatric infectious diseases. This clinical study found no adverse side effects in children receiving the medication.
Area of Science:
- Pharmacology
- Pediatrics
- Infectious Diseases
Context:
- Norfloxacin (AM-715) is a novel synthetic antibacterial agent.
- Pediatric infectious diseases require effective and safe treatment options.
Purpose:
- To evaluate the clinical efficacy and safety of Norfloxacin in pediatric patients.
- To assess the therapeutic outcomes and adverse events associated with Norfloxacin treatment in children.
Summary:
- Eighteen pediatric patients (3-14 years) with infectious diseases received oral Norfloxacin (5.2-17.9 mg/kg/day) for 4-14 days.
- Clinical efficacy was rated as excellent in 1 case and good in 16 cases, with an overall efficacy rate of 100%.
- No adverse side effects or abnormal laboratory values were reported during the treatment period.
Impact:
- Norfloxacin shows promising efficacy and excellent safety profile for treating pediatric infectious diseases.
- This study supports Norfloxacin as a potential therapeutic option for bacterial infections in children.
- The findings highlight the need for further research into Norfloxacin's role in pediatric infectious disease management.
Abstract:
Norfloxacin (NFLX, AM-715), a new synthetic antibacterial agent, was administered to 18 child patients with infectious diseases. The patients included 5 boys and 13 girls from 3 to 14 years of ages. They were given orally dosage ranging 5.2-17.9 mg/kg/day for 4 to 14 days. Clinical efficacies were excellent in 1 case, good in 16 cases, unknown in 1 case, hence the total efficacy rate was determined to be 100%. There were no cases which showed side effects of the drug and no abnormal laboratory test values were observed during the treatment.